We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

39 hedge funds and large institutions have $155M invested in CRISPR Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

11% more funds holding

Funds holding: 35 → 39 (+4)

0.2% less ownership

Funds ownership: 24.29% → 24.09% (-0.2%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

26% less capital invested

Capital invested by funds: $211M → $155M (-$55.7M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $322K

Holders
39
Holders Change
+4
Holders Change %
+11.43%
% of All Funds
0.97%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
9
Increased
6
Reduced
8
Closed
5
Calls
$1K
Puts
$322K
Net Calls
-$321K
Net Calls Change
-$321K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$12M
2
GIM
Granahan Investment Management
Massachusetts
+$2.87M
3
USAA
United Services Automobile Association
Texas
+$996K
4
Millennium Management
Millennium Management
New York
+$545K
5
RJA
Raymond James & Associates
Florida
+$331K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.3M
2
A
Abingworth
United Kingdom
-$2.59M
3
NLVP
New Leaf Venture Partners
New York
-$970K
4
CCP
Clough Capital Partners
Massachusetts
-$456K
5
PC
Paulson & Co
New York
-$363K
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
26
Advisor Group
Arizona
$14K +$9.91K +600 +200%
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Quebec, Canada
$12.8K +$2.51K +152 +23%
LWCFA
28
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$10K – – –
Deutsche Bank
29
Deutsche Bank
Germany
$8K -$106K -6,400 -93%
MFW
30
Mosaic Family Wealth
Missouri
$8K – – –
CFA
31
Carroll Financial Associates
North Carolina
$7K – – –
IP
32
Intellectus Partners
California
$7K – – –
KF
33
Krilogy Financial
Missouri
$5K +$4.96K +300 New
CG
34
Cutler Group
California
$5K +$5.57K +337 New
ASN
35
Advisory Services Network
Georgia
$2K – – –
LTFS
36
Ladenburg Thalmann Financial Services
Florida
$2K – – –
WIM
37
Westside Investment Management
California
$1.6K – – –
CCM
38
Cribstone Capital Management
Maine
$1K – – –
IWM
39
IHT Wealth Management
Illinois
$20 +$1.32K +80 +1%
Wellington Management Group
40
Wellington Management Group
Massachusetts
– -$16.3M -747,450 Closed
DSI
41
Daiwa SB Investments
Japan
– -$61K -2,800 Closed
TDC
42
Thompson Davis & Co
Virginia
– -$54K -2,500 Closed
Citigroup
43
Citigroup
New York
– -$2K -100 Closed
US Bancorp
44
US Bancorp
Minnesota
– -$1K -39 Closed
1
2

CRSP Hedge Fund Activity: Q2 2017 in Review

39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2017, worth a combined $155M — down 26% from $211M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRSP positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12M. The largest seller was Wellington Management Group, exiting entirely with an estimated $16.3M sold.

  • 39 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2017, up from 35 in Q1 2017.
  • Funds reported $155M of CRISPR Therapeutics stock for Q2 2017, down 26% quarter-over-quarter.
  • 9 funds opened new CRISPR Therapeutics positions in Q2 2017 and 5 closed out, a net change of +4 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2017 was Morgan Stanley, an estimated $12M added.
  • The largest CRISPR Therapeutics seller in Q2 2017 was Wellington Management Group, an estimated $16.3M sold.

Based on aggregated 13F filings for Q2 2017.